a year ago
SRPT
AnalystsGil BlumGil Blum's Stock Forecasts
AnalystsGil Blum
Sectors:
Industries:
Analyst Ranking
Top 4%
#193 out of 5223 analysts
Average Return
+9.74%
Win Rate
38%176 out of 468
Risk vs Reward
Poor
Good
Gil Blum's 5 best and worst ratings
| Name / Ticker | Gain/Loss | Entry Price | Exit Price | Period | Rating |
|---|---|---|---|---|---|
Celcuity IncCELC | +1,048.86% | $9.23 | $106.04 | 2025-04-11 - 2026-03-20 | Buy |
Celcuity IncCELC | +1,041.44% | $9.29 | $106.04 | 2025-04-01 - 2026-03-20 | Buy |
Celcuity IncCELC | +907.98% | $10.52 | $106.04 | 2025-05-15 - 2026-03-20 | Buy |
Celcuity IncCELC | +728.28% | $12.59 | $104.28 | 2025-02-06 - 2026-02-05 | Buy |
Celcuity IncCELC | +694.31% | $13.35 | $106.04 | 2025-06-30 - 2026-03-20 | Buy |
Gil Blum Analyst Color
Get additional color on Gil Blum's coverage of popular stocks
2 years ago
AUTL
2 years ago
AUTL
Gil Blum's Stock Coverage
| Name / Ticker | No. Ratings | Rating | Price Target | Upside/Downside | Action | Date |
|---|---|---|---|---|---|---|
Solid Biosciences IncSLDB | 4 | Buy | $19.00 | +170.27% | Reiterates | 2 days ago |
Taysha Gene Therapies IncTSHA | 33 | Buy | $12.00 | +172.73% | Maintains | 3 days ago |
Absci CorpABSI | 8 | Buy | $7.00 | +136.49% | Reiterates | 4 days ago |
Celcuity IncCELC | 23 | Buy | $122.00 | +15.05% | Reiterates | 5 days ago |
Artiva Biotherapeutics IncARTV | 8 | Buy | $18.00 | +238.35% | Reiterates | 11 days ago |
Cartesian Therapeutics IncRNAC | 25 | Buy | $42.00 | +545.16% | Reiterates | 13 days ago |
Immunocore Holdings PLCIMCR | 15 | Buy | $75.00 | +150.75% | Maintains | 24 days ago |
Recursion Pharmaceuticals IncRXRX | 26 | Buy | $8.00 | +146.15% | Reiterates | 24 days ago |
Crispr Therapeutics AgCRSP | 28 | Buy | $82.00 | +77.34% | Maintains | a month ago |
Arcellx IncACLX | 24 | Buy | $105.00 | -8.51% | Reiterates | a month ago |
Nurix Therapeutics IncNRIX | 29 | Buy | $26.00 | +80.18% | Reiterates | 2 months ago |
Mereo Biopharma Group PLCMREO | 21 | Buy | $3.00 | +777.19% | Maintains | 2 months ago |
Autolus Therapeutics PLCAUTL | 34 | Buy | $10.00 | +629.93% | Maintains | 2 months ago |
Geron CorpGERN | 23 | Buy | $4.00 | +173.97% | Maintains | 5 months ago |
Tscan Therapeutics IncTCRX | 8 | Buy | $6.00 | +476.92% | Maintains | 5 months ago |
Amicus Therapeutics IncFOLD | 2 | Buy | $14.00 | -2.98% | Upgrades | 6 months ago |
Novabridge BiosciencesNBP | 17 | Buy | $6.00 | +134.38% | Reiterates | 6 months ago |
Generation Bio CoGBIO | 18 | Buy | $15.00 | +180.90% | Reiterates | 7 months ago |
Nkarta IncNKTX | 17 | Buy | $10.00 | +367.29% | Reiterates | 7 months ago |
Sarepta Therapeutics IncSRPT | 33 | Hold | $50.00 | +199.58% | Downgrades | 8 months ago |
Rocket Pharmaceuticals IncRCKT | 21 | Hold | $42.00 | +914.49% | Downgrades | 10 months ago |
Shattuck Labs IncSTTK | 13 | Hold | $8.00 | N/A | Downgrades | a year ago |
Nextcure IncNXTC | 9 | Buy | $48.00 | N/A | Reiterates | 2 years ago |
G1 Therapeutics IncGTHX | 17 | Buy | $6.00 | N/A | Maintains | 2 years ago |
Gamida Cell LtdGMDAQ | 8 | Buy | $6.00 | N/A | Reiterates | 2 years ago |
Cti Biopharma CorpCTIC | 5 | Buy | $9.00 | N/A | Reiterates | 3 years ago |
Tectonic Therapeutic IncTECX | 4 | Buy | $72.00 | N/A | Reiterates | 3 years ago |
Fate Therapeutics IncFATE | 1 | Hold | N/A | N/A | Initiates Coverage On | 4 years ago |
Spyre Therapeutics IncSYRE | 1 | Buy | $225.00 | N/A | Maintains | 4 years ago |
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.